Allakos Analyst Turns Bullish, Sees 'Significant Upside' If Study Results Are Positive
Portfolio Pulse from Priya Nigam
Allakos Inc (NASDAQ:ALLK) shares rose after William Blair analyst Tim Lugo upgraded the company to Outperform, citing a 'strong chance' of efficacy in upcoming study results for lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Lugo highlighted the significant upside potential if the studies prove successful, especially given Allakos's current low enterprise value compared to Celldex, which has a much higher valuation after positive Phase II data in CSU.
December 18, 2023 | 5:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allakos Inc's stock received an upgrade to Outperform by William Blair analyst Tim Lugo, who anticipates potential positive study results for lirentelimab. The company's low valuation compared to peers suggests room for significant upside.
The upgrade by a reputable analyst based on the potential positive outcome of upcoming studies is a strong positive signal for investors. Given the low enterprise value of Allakos compared to its peer Celldex, there is a perceived significant upside which could lead to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100